What changed this week
Patterns across the week's 79 stories; each point names the stories it rests on.
- India’s 30% margin cap targets ₹2,500 Cr annual savings, making affordable regimens and help navigating medicine costs central to patient access.Stories 79
- Blood tests may help tailor treatment: one guided less chemotherapy without worse long-term outcomes, while another report describes actionable but unstandardized tumour DNA testing.Stories 41, 31
- Treatment benefit can differ by cancer subgroup: blinatumomab outcomes varied across adult leukemia subtypes, while gene fusions marked poorer survival without targeted treatment.Stories 15, 42
- Engineered immune cells are being adapted to withstand solid tumour defences in preclinical studies, a research direction relevant to future solid tumour cell therapy work.Stories 64, 72, 75
Clinical trials
- Cabozantinib led to responses in pretreated non-small cell lung cancerStory 18
- Glofitamab combination led to complete responses in diffuse large B-cell lymphomaStory 28
- Cryotherapy tested to prevent nerve damage during taxane cancer treatmentStory 29
- Tile-based radiation cut recurrence after surgery for liver cancer brain metastasesStory 40
- Niraparib showed activity in advanced ovarian cancer before surgeryStory 44
- FDA approves tucatinib combination for maintenance treatment of breast cancerStory 53
- Robotic surgery removed more lymph nodes in food pipe cancerStory 55
- Varegacestat shrank desmoid tumors in a phase II trialStory 57
- Alectinib shrank advanced solid tumors in a phase II trialStory 58
- FDA approves atezolizumab with chemotherapy for stage III colon cancerStory 69
- Five-year colonoscopy timing matched three years for colorectal cancerStory 71
Precision oncology
- Study finds protein-form switches in acute myeloid leukemiaStory 2
- Study links blinatumomab benefit to subtypes of adult acute lymphoblastic leukemiaStory 15
- Continuous BTK inhibitors kept chronic lymphocytic leukemia in check for about 7 yearsStory 16
- FDA approves daraxonrasib for pancreatic cancerStory 26
- Lab-grown kidney models reveal origins of Wilms tumorStory 30
- Ablation did not improve outcomes in oligometastatic breast cancerStory 38
- Blinatumomab improves outcomes in high-risk childhood acute lymphoblastic leukemiaStory 39
- A blood test reduced chemotherapy use in stage II colon cancerStory 41
- Gene fusions linked to shorter survival in adults with advanced cancersStory 42
- Sunitinib showed activity in several solid tumor cancersStory 43
Antibody-drug conjugates
- Drug combination helped older patients with diffuse large B-cell lymphomaStory 13
- Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced hepatocellular carcinoma Who Have Failed or Progressed on Standard Systemic Therapy Containing immune checkpoint inhibitorsStory 34
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on TumorsStory 48
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaStory 49
- Aragen Life Sciences begins operations at high-potency platform in HyderabadStory 52
- Drug combination shrank very high-risk bladder cancer in a phase 2 trialStory 54
- Sofetabart tested in high-grade ovarian cancerStory 56
India access
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian CancerStory 11
- Getting glutathione into the blood is not the same as getting glutathione into the cellStory 23
- CERVAVAC receives WHO prequalificationStory 24
- We aim to be a truly integrated partner across modalitiesStory 25
- Integration is the real barrier to AI in hospitals: ExpertsStory 37
- Government caps margins on cancer medicines at 30%, targets ₹2,500 Cr annual savingsStory 79
Cell and gene therapy
- A mutation linked to cisplatin resistance in hypopharyngeal squamous cell carcinomaStory 1
- Blocking a nutrient transporter helped immunotherapy fight glioblastoma in miceStory 17
- In vivo immune-cell therapy had mixed results in multiple myelomaStory 27
- New treatments extend survival for people with multiple myelomaStory 59
- INSR engineering protected immune cells from gastrointestinal cancer stromaStory 72
Radiopharmaceuticals
Cancer-care delivery
Gene therapy
Solid-tumor CAR-T
Cancer vaccines
Other
- A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trialStory 3
- Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor ResistanceStory 4
- Gut microbiome features associated with PIK3CA-mutated colorectal cancer: A nationwide pan-cancer genomic and microbial profiling study (MONSTAR-SCREEN)Story 5
- FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast CancerStory 7
- FDA Approves First-Line Pirtobrutinib for CLL-SLLStory 8
- A Study of PTX-9908 Injection for Non-resectable hepatocellular carcinoma With TACEStory 9
- Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeStory 10
- STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphomaStory 19
- Endotrophin is a circulating fibroinflammatory biomarker associated with treatment response in human metastatic ER+ breast cancerStory 20
- Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal CancerStory 21
- circulating tumour DNA in muscle-invasive bladder cancer — clinically actionable, not yet standardizedStory 31
- Inferring clinically relevant molecular subtypes of pancreatic cancer from routine histopathology using deep learningStory 32
- Automated acquisition of thyroid cytology image features using self-supervised learning and application to image classificationStory 35
- A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerStory 36
- Human microglia clear intraneuronal α-synuclein aggregates by GPNMB-mediated trogocytosisStory 45
- Pediatric Bone Sarcoma Gets First NCCN GuidelinesStory 46
- Unlocking 30-Year-Old Archival Formalin-Fixed Paraffin-Embedded Breast Cancer Specimens (SWOG S8897): An Analytical Feasibility StudyStory 47
- HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance TherapyStory 50
- Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid TumorsStory 51
- Multimodal Gene Expression Deep Learning for Predicting Sentinel Lymph Node Macro-metastasis in Early Breast Cancer: Development and Validation in the SCAN-B CohortStory 60
- ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic PopulationStory 61
- Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate CancerStory 62
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyStory 65
- STAT+: Roche goes beyond licensing in deal with Chinese biotechStory 66
- FDA Approves New Labeling of ROS1 Inhibitor for non-small cell lung cancerStory 67
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Story 68
- A modular framework for antibody–drug conjugate biomarkersStory 73
- A pan-cancer analysis of TLK1 and TLK2: genomic instability, immunomodulation, and therapeutic implicationsStory 74
- FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon CancerStory 76
- ATF5 promotes redox homeostasis and cancer progression through nuclear-mitochondrial collaboration in pancreatic cancerStory 77
- FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCCStory 78